Syros Pharmaceuticals (SYRS)
Oppenheimer analyst Leah R. Cann assigned a Buy rating to Syros Pharmaceuticals yesterday and set a price target of $28. The company’s shares closed yesterday at $12.74.
“The discussion with KOLs strongly supports the development of SY-1425 in AML and high-risk MDS in combination with hypomethylating agents (HMAs) and with anti- CD38 therapy. We continue to expect data from these combination cohorts in Q4 2018. We estimate that SY-1425 will account for 100% of Syros’ 2022 revenue, and believe that near-term clinical results for SY-1425 are the biggest driver of value for Syros. The views expressed by Drs. Cook and Stein today are consistent with those of investigators at the 2017 ASH meeting.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 27.8% and a 61.4% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Syros Pharmaceuticals is a Moderate Buy with an average price target of $19, a 49.1% upside from current levels. In a report released yesterday, Cowen & Co. also assigned a Buy rating to the stock.
Mesoblast Ltd (MESO)
In a report released yesterday, Mark Breidenbach from Oppenheimer reiterated a Buy rating on Mesoblast Ltd, with a price target of $16. The company’s shares closed yesterday at $6.75.
“Tuesday, Mesoblast announced a strategic alliance with Chinese rights to two of Mesoblast’s cell therapies: MPC-150-IM for congestive heart failure (CHF) and MPC-25-IC for acute myocardial infarction. The agreement comes with a $40M upfront payment, including a $20M equity stake priced at a ~20% premium to Mesoblast’s 3-month average share price, and could provide Mesoblast with a future stream of royalty and milestone revenue. We believe Mesoblast’s rich pipeline could provide additional partnership opportunities in Asia and other territories. Recall, Mesoblast’s cell therapy for graft-vs-host disease is already partnered with JCR Pharmaceuticals and is being marketed in Japan. We estimate the upfront from Tasly could extend Mesoblast’s operational runway until 4Q19, and we reiterate our Outperform rating and $16 PT.”
According to TipRanks.com, Breidenbach is a 4-star analyst with an average return of 13.4% and a 42.0% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Alpine Immune Sciences Inc, and Global Blood Therapeutics.
Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $17.50, which is a 159.3% upside from current levels. In a report issued on July 2, H.C. Wainwright also maintained a Buy rating on the stock with a $17 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.